{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T20:24:45Z","timestamp":1769804685029,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shenzhen Chipscreen Biosciences Co., Ltd","award":["F24000852"],"award-info":[{"award-number":["F24000852"]}]},{"name":"Shenzhen Chipscreen Biosciences Co., Ltd","award":["F24003871"],"award-info":[{"award-number":["F24003871"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-025-09339-y","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T01:26:08Z","timestamp":1765329968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional \u201c3\u2009+\u20097\u201d intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial"],"prefix":"10.1186","volume":"27","author":[{"given":"Honghong","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengxin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peilong","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5446-292X","authenticated-orcid":false,"given":"Jianyu","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"9339_CR1","doi-asserted-by":"crossref","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators.Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1789\u20131858.","DOI":"10.1016\/S0140-6736(18)32279-7"},{"issue":"17","key":"9339_CR2","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1001\/jama.2011.1558","volume":"306","author":"ML Sorror","year":"2011","unstructured":"Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306(17):1874\u201383.","journal-title":"JAMA"},{"issue":"35","key":"9339_CR3","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1200\/JCO.2015.62.7273","volume":"33","author":"SM Devine","year":"2015","unstructured":"Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, et al. Phase study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: results from Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)\/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015;33(35):4167\u201375.","journal-title":"J Clin Oncol"},{"issue":"12","key":"9339_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"key":"9339_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","journal-title":"Blood Rev"},{"issue":"18","key":"9339_CR6","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf A, Lehmann S, M\u00f6llg\u00e5rd L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179\u201387.","journal-title":"Blood"},{"issue":"9757","key":"9339_CR7","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1016\/S0140-6736(10)62105-8","volume":"376","author":"U Krug","year":"2010","unstructured":"Krug U, Rollig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet. 2010;376(9757):2000\u20138.","journal-title":"Lancet"},{"issue":"7","key":"9339_CR8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"key":"9339_CR9","doi-asserted-by":"crossref","unstructured":"Evan M. Cherry, Diana Abbott, Maria Amaya,Christine McMahon, Marc Schwartz Julie Rosser, et al. Gutman, and Daniel A. Pollyea. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021;5(24):5565\u20135573.","DOI":"10.1182\/bloodadvances.2021005538"},{"key":"9339_CR10","doi-asserted-by":"crossref","unstructured":"LI Z, Zhang H, LI Y, Chen L, Dai H, Zhou H, et al. P518: Venetoclax and azacitidine combined with chidamide (VAC) for the treatment of newly diagnosed acute monocytic leukemia patients.\u00a0Hemasphere. 2023;7(Suppl ):e204697f.","DOI":"10.1097\/01.HS9.0000968980.20469.7f"},{"key":"9339_CR11","doi-asserted-by":"crossref","unstructured":"Konopleva M, D. Dinardo C, Sun Y, Loghavi S, Jung P, Potluri J,\u00a0et al.P521: findings from an analysis of patients with monocytic and monocytic-like acute myeloid leukemia (AML), including AML-M4 AND AML-M5, treated with venetoclax (VEN) plus azacitidine (AZA).\u00a0Hemasphere. 2023;7(Suppl ):e160928c.","DOI":"10.1097\/01.HS9.0000968992.16092.8c"},{"issue":"Supplement 1","key":"9339_CR12","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1182\/blood-2022-165261","volume":"140","author":"J Zha","year":"2022","unstructured":"Zha J, Zhou H, Zhong M, Wang Y, Xin Du, Gong T, et al. Preclinical studies and phase II trial of venetoclax in combination with chidamide and azacitidine in relapsed\/refractory acute myeloid leukemia. Blood. 2022;140(Supplement 1):3292\u20133.","journal-title":"Blood"},{"issue":"Supplement 1","key":"9339_CR13","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2023-188196","volume":"142","author":"J Weng","year":"2023","unstructured":"Weng J, Huang X, Wu P, Deng C, Li M, Chen X, et al. ABC regimen (azacitidine, venetoclax and chidamide) is comparable to the \u201c3+7\u201d regimen in newly diagnosed AML: a real-world experience from South China. Blood. 2023;142(Supplement 1):1522.","journal-title":"Blood"},{"issue":"11","key":"9339_CR14","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jval.2019.06.004","volume":"22","author":"F Efficace","year":"2019","unstructured":"Efficace F, Cottone F, Sommer K, Kieffer J, Aaronson N, Fayers P, et al. Validation of the European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 summary score in patients with hematologic malignancies. Value Health. 2019;22(11):1303\u201310.","journal-title":"Value Health"},{"issue":"26","key":"9339_CR15","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","volume":"383","author":"AH Wei","year":"2020","unstructured":"Wei AH, D\u00f6hner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020;383(26):2526\u201337.","journal-title":"N Engl J Med"},{"key":"9339_CR16","unstructured":"Jianyu Weng, Chengxin Deng, Ping Wu, Yuming Zhang, Minming Li, Xin Huang, Zhenqian Huang, Xu Ye, Yirong Jiang, Li\u2019e Lin, Runhui Zheng, Xiaoliang Li, Chengwei Lou, Peilong Lai, Yangqiu Li, Xin Du. ABC-14 regimen(Azacitidine, Venetoclax and Chidamide) is comparable to \u201c3+7\u201d regimen in de novo AML: a real world experience from ABC-14 collaboration group.(Abstract release date:05\/14\/24)\u00a0EHA Library.\u00a0Wu P.\u00a006\/13\/2024;\u00a0421239;\u00a0PB2492."},{"issue":"10159","key":"9339_CR17","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","volume":"392","author":"KJ Foreman","year":"2018","unstructured":"Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016\u201340 for 195 countries and territories. Lancet. 2018;392(10159):2052\u201390.","journal-title":"Lancet"},{"issue":"2","key":"9339_CR18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1080\/10428194.2017.1330956","volume":"59","author":"PratzKW WebsterJA","year":"2018","unstructured":"WebsterJA PratzKW. Acute myeloid leukemia in the elderly: therapeutic options and choice. Leuk Lymphoma. 2018;59(2):274\u201387.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"9339_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","volume":"19","author":"DA Pollyea","year":"2021","unstructured":"Pollyea DA, Bixby D, Perl A, et al. NCCN guidelines insights: acute myeloid leukemia, version 2.2021. J Natl Compr Canc Netw. 2021;19(1):16\u201327.","journal-title":"J Natl Compr Canc Netw"},{"issue":"15","key":"9339_CR20","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1182\/blood-2010-04-279794","volume":"116","author":"M Miesner","year":"2010","unstructured":"Miesner M, Haferlach C, Bacher U, Weiss T, Macijewski K, Kohlmann A, et al. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS - related cytogenetic abnormalities and a prior history of MDS or MDS\/MPN but has no independent prognostic relevance: A comparison of 408 cases classified as \u2018AML not otherwise specified\u2019 (AML -NOS) or \u2018AML with myelodysplasia-related changes\u2019 (AML-MRC). Blood. 2010;116(15):2742\u201351.","journal-title":"Blood"},{"issue":"20","key":"9339_CR21","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"31","key":"9339_CR22","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","volume":"33","author":"LS Granfeldt \u00d8stg\u00e5rd","year":"2015","unstructured":"Granfeldt \u00d8stg\u00e5rd LS, Medeiros BC, Sengel\u00f8v H, N\u00f8rgaard M, Andersen MK, Dufva IH, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population - based cohort study. J Clin Oncol. 2015;33(31):3641\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"9339_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med"},{"key":"9339_CR24","doi-asserted-by":"crossref","unstructured":"Schulz KF, Altman DG, Moher D;CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18\u201326.","DOI":"10.1186\/1741-7015-8-18"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09339-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09339-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09339-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:58:57Z","timestamp":1769767137000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-025-09339-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9339"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09339-y","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The funding section has been updated.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of Guangdong Provincial People\u2019s Hospital has approved the trial protocol (version 1.0\u201401 Jun 2023), with an ethics approval number of KY2023-1057\u201303. Written informed consent to participate will be obtained from all study participants. The principal investigator will ensure that the study is conducted in accordance with the protocol and complies with ICH Good Clinical Practice Guidelines, the Helsinki Declaration, and all regulatory and institutional requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}